Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 42: 558-563, 1996;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Guechot, J.
Right arrow Articles by Giboudeau, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guechot, J.
Right arrow Articles by Giboudeau, J.

Clinical Chemistry, Vol 42, 558-563, Copyright © 1996 by American Association for Clinical Chemistry

Diagnostic accuracy of hyaluronan and type III procollagen amino- terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis

J Guechot, A Laudat, A Loria, L Serfaty, R Poupon and J Giboudeau
Service de Biochimie A, Hopitaux de Paris, Hopital Saint-Antoine, Paris, France.

Diagnostic accuracy of two serum markers of liver fibrosis, hyaluronan (HA) and amino-terminal peptide of type III procollagen (P-III-P), was studied in a cohort of 326 untreated patients with chronic viral hepatitis C. Both P-III-P (RIA-gnost P-III-P, Behring Diagnostic) and HA (HA-test, Pharmacia) serum concentrations correlated with the histological grades of liver fibrosis (P < 0.001). Receiver-operating characteristic (ROC) curves showed that serum HA had greater diagnostic performance than P-III-P, both for discriminating patients with extensive liver fibrosis from those with no or mild fibrosis (area under the ROC curves: 0.864 vs 0.691, P <0.001) or for discriminating patients with cirrhosis from those without cirrhosis (area under the ROC curves: 0.924 vs 0.734, P <0.001). At cutoff values of 0.8 kU/L for serum P-III-P and 85 micrograms/L for serum HA, sensitivities were 70.0% and 64.5%, and specificities were 63.4% and 91.2%, respectively, for discriminating patients with extensive liver fibrosis from those with no or mild fibrosis. At the cutoff values of 1.0 kU/L for serum P- III-P and 110 micrograms/L for serum HA, sensitivities were 60.0% and 79.2%, and specificities were 74.0% and 89.4%, respectively, for discriminating patients with liver cirrhosis from those without cirrhosis. We conclude that, because the diagnostic accuracy of serum HA is greater than that of serum P-III-P as a marker of liver fibrosis, serum HA should be preferred when monitoring liver fibrosis in patients with chronic viral hepatitis C.


The following articles in journals at HighWire Press have cited this article:


Home page
 Mol. Cell. ProteomicsHome page
D. Vanderschaeghe, W. Laroy, E. Sablon, P. Halfon, A. Van Hecke, J. Delanghe, and N. Callewaert
GlycoFibroTest Is a Highly Performant Liver Fibrosis Biomarker Derived from DNA Sequencer-based Serum Protein Glycomics
Mol. Cell. Proteomics, May 1, 2009; 8(5): 986 - 994.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
L. Huwart, C. Sempoux, N. Salameh, J. Jamart, L. Annet, R. Sinkus, F. Peeters, L. C. ter Beek, Y. Horsmans, and B. E. Van Beers
Liver Fibrosis: Noninvasive Assessment with MR Elastography versus Aspartate Aminotransferase to-Platelet Ratio Index
Radiology, November 1, 2007; 245(2): 458 - 466.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
M. Friedrich-Rust, M.-F. Ong, E. Herrmann, V. Dries, P. Samaras, S. Zeuzem, and C. Sarrazin
Real-Time Elastography for Noninvasive Assessment of Liver Fibrosis in Chronic Viral Hepatitis
Am. J. Roentgenol., March 1, 2007; 188(3): 758 - 764.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
I N Guha, J Parkes, P R Roderick, S Harris, and W M Rosenberg
Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease.
Gut, November 1, 2006; 55(11): 1650 - 1660.
[Full Text] [PDF]

Home page
 GutHome page
M Pinzani
Non-invasive evaluation of hepatic fibrosis: don't count your chickens before they're hatched
Gut, March 1, 2006; 55(3): 310 - 312.
[Full Text] [PDF]

Home page
 Br. J. Radiol.Home page
T Nishiura, H Watanabe, M Ito, Y Matsuoka, K Yano, M Daikoku, H Yatsuhashi, K Dohmen, and H Ishibashi
Ultrasound evaluation of the fibrosis stage in chronic liver disease by the simultaneous use of low and high frequency probes
Br. J. Radiol., March 1, 2005; 78(927): 189 - 197.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
B. Lumbreras-Lacarra, J. M. Ramos-Rincon, and I. Hernandez-Aguado
Methodology in Diagnostic Laboratory Test Research in Clinical Chemistry and Clinical Chemistry and Laboratory Medicine
Clin. Chem., March 1, 2004; 50(3): 530 - 536.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
I. Ryden, P. Pahlsson, and S. Lindgren
Diagnostic Accuracy of {alpha}1-Acid Glycoprotein Fucosylation for Liver Cirrhosis in Patients Undergoing Hepatic Biopsy
Clin. Chem., December 1, 2002; 48(12): 2195 - 2201.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
D. R. Dufour, J. A. Lott, F. S. Nolte, D. R. Gretch, R. S. Koff, and L. B. Seeff
Diagnosis and Monitoring of Hepatic Injury. II. Recommendations for Use of Laboratory Tests in Screening, Diagnosis, and Monitoring
Clin. Chem., December 1, 2000; 46(12): 2050 - 2068.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
S. Harvey, M. Weisman, J. O'Dell, T. Scott, M. K. J. Visor, and C. Swindlehurst
Chondrex: new marker of joint disease
Clin. Chem., March 1, 1998; 44(3): 509 - 516.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the American Association for Clinical Chemistry.